KRIBIOLISA™ Exenatide (Byetta) ELISA

Bipharma - Others; Other Biopharma / Vaccine ELISA; Peptide Drug ELISA

Enzyme Immunoassay for the quantitative estimation of Exenatide in serum, plasma and cell culture supernatant

Introduction:
Exenatide or Extendin-4 is a potent GLP-1 receptor agonist. Exenatide (marketed as Byetta) is one of a new class
of medications (incretin mimetics) approved (in April 2005) for the treatment of diabetes mellitus type 2 (It was not
approved for use in diabetes mellitus type 1).

Intended Use:
The KRIBIOLISA™ Exenatide ELISA is used as for the quantitative determination of Exenatide in serum,
plasma and cell culture supernatant.

Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Exenatide are
pre-coated onto microwells. Samples and standards are pipetted into microwells and Exenatide present
in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated antiExenatide antibody is pipetted and incubated with samples. After washing microwells in order to remove
any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color
develops proportionally to the amount of Exenatide in the sample. Color development is then stopped by
addition of stop solution. Absorbance is measured at 450 nm.